Farther Finance Advisors’s CytomX Therapeutics CTMX Stock Holding History

Farther Finance Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$7.79K	Sell	2,865 -304	-10%	-$1.01K	﹤0.01%	4770
2026 Q2	$11.9K	Sell	3,169 -4,706	-60%	-$18K	﹤0.01%	4312
2026 Q1	$35.9K	Hold	7,875	–	–	﹤0.01%	3229
2025 Q4	$33.5K	Sell	7,875 -95	-1%	-$361	﹤0.01%	3082
2025 Q3	$25.4K	Buy	+7,970	New	+$17.9K	﹤0.01%	2871

Other funds holding CTMX

IRC

Investors Research Corp Atlanta, Georgia $569M AUM 15.41% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors's CTMX Position: Q3 2026 in Review

Farther Finance Advisors reduced its CytomX Therapeutics (CTMX) stake by 9.6% in Q3 2026, selling an estimated $1.01K and leaving 2,865 shares worth $7.79K. The position accounts for ﹤0.01% of the portfolio, ranked #4770.

Farther Finance Advisors first reported a position in CTMX in Q3 2025 and has held it in 5 quarters since. The position peaked at $35.9K in Q1 2026. 3 funds tracked by Wall St. Rank hold CTMX as of Q3 2026.

Farther Finance Advisors held 2,865 shares of CytomX Therapeutics worth $7.79K as of Q3 2026.
Farther Finance Advisors sold 304 CytomX Therapeutics shares in Q3 2026, an estimated $1.01K.
CytomX Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #4770 holding.
Farther Finance Advisors first reported a position in CytomX Therapeutics in Q3 2025 and has held it in 5 quarters since.
Farther Finance Advisors's CytomX Therapeutics position peaked at $35.9K in Q1 2026.
3 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.